| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1365-2125.1979.TB00896.X |
| P953 | full work available at URL | https://europepmc.org/articles/PMC1429596 |
| https://europepmc.org/articles/PMC1429596?pdf=render | ||
| P932 | PMC publication ID | 1429596 |
| P698 | PubMed publication ID | 760742 |
| P5875 | ResearchGate publication ID | 22381065 |
| P2093 | author name string | C. F. George | |
| C. M. Castleden | |||
| P2860 | cites work | The disposition of propranolol. I. Elimination during oral absorption in man | Q70440090 |
| Influence of the route of administration on the area under the plasma concentration-time curve | Q72340804 | ||
| Changes in cardiac output with age | Q73820569 | ||
| Adrenocortical function and cortisol metabolism in old age | Q76420011 | ||
| THE EFFECT OF INCREASING AGE ON THE DISTRIBUTION OF PERIPHERAL BLOOD FLOW IN MAN | Q78273811 | ||
| Splanchnic blood flow in man by the bromsulfalein method: the relation of peripheral plasma bromsulfalein level to the calculated flow | Q80702222 | ||
| Plasma binding and the affinity of propranolol for a beta receptor in man | Q28333902 | ||
| Influence of route of administration on drug availability | Q34226637 | ||
| Changes in drug metabolism with increasing age: 1. warfarin binding and plasma proteins | Q34451452 | ||
| Changes in drug metabolism with increasing age: 2. phenytoin clearance and protein binding | Q34451491 | ||
| Factors affecting drug binding in plasma of elderly patients | Q34515177 | ||
| Effect of age on liver function with particular reference to bromsulphalein excretion | Q35002527 | ||
| A four parameter model for oral drug absorption | Q39109186 | ||
| Pharmacokinetic properties of the beta-adrenergic receptor blocking drugs | Q39874224 | ||
| The disposition of propranolol. II. Hepatic elimination in the rat. | Q43727451 | ||
| Commentary: a physiological approach to hepatic drug clearance | Q43996648 | ||
| Plasma propranolol levels in adults With observations in four children | Q45077479 | ||
| Effect of Age and Sex on Human Drug Metabolism | Q50348052 | ||
| Pharmacological implications of microsomal enzyme induction. | Q52474261 | ||
| Disposition of propranolol. V. Drug accumulation and steady-state concentrations during chronic oral administration in man. | Q52939660 | ||
| The disposition of propranolol. 3. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat | Q67251918 | ||
| Antipyrine metabolism in man: influence of age, alcohol, caffeine, and smoking | Q67273626 | ||
| Contribution of the liver to overall elimination of propranolol | Q67452899 | ||
| Effect of phenobarbital on electron transport system, oxidation and reduction of drugs in liver microsomes of rats of different age | Q68581962 | ||
| Plasma propranolol levels in the quaniitative assessment of beta-adrenergic blockade in man | Q68748950 | ||
| The hemodynamic effects of beta adrenergic blockade on the flow-dependent hepatic clearance of propranolol | Q69381509 | ||
| Adverse reactions to propranolol in hospitalized medical patients: A report from the Boston Collaborative Drug Surveillance Program | Q69567412 | ||
| The disposition of propranolol. 8. General implications of the effects of liver blood flow on elimination from the perfused rat liver | Q70043133 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | human ageing | Q332154 |
| P304 | page(s) | 49-54 | |
| P577 | publication date | 1979-01-01 | |
| P1433 | published in | British Journal of Clinical Pharmacology | Q176044 |
| P1476 | title | The effect of ageing on the hepatic clearance of propranolol | |
| P478 | volume | 7 |
| Q34447166 | A comparison of the pharmacokinetics of atenolol, metoprolol, oxprenolol and propranolol in elderly hypertensive and young healthy subjects |
| Q70788228 | A propranolol radioimmunoassay and its use in the study of its pharmaco‐kinetics following low doses |
| Q36642205 | A standard approach to compiling clinical pharmacokinetic data |
| Q39502346 | Acebutolol: a review of its pharmacology, pharmacokinetics, clinical uses, and adverse effects |
| Q38031400 | Adverse drug reactions. An overview of special considerations in the management of the elderly patient |
| Q52289474 | Age-dependent alteration of the serum-unbound fraction of nicardipine, a calcium-channel blocker, in man. |
| Q36215697 | Age-related changes in hepatic function. Implications for drug therapy |
| Q39618055 | Age-related changes in liver size and hepatic blood flow. The influence on drug metabolism in the elderly |
| Q35608904 | Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. |
| Q40627715 | Age-related changes in the gastrointestinal system. Effects on drug therapy |
| Q70460490 | Age-related differences in kinetics and side-effects of viloxazine in man and their clinical implications |
| Q38323527 | Alterations in drug disposition in older adults. |
| Q37919206 | Altered pharmacokinetics in the elderly. |
| Q36545937 | Antihypertensive therapy in the aged patient. Clinical pharmacokinetic considerations |
| Q51026059 | Atrial fibrillation in the elderly: a review. |
| Q34635476 | BJCP 40th anniversary: moving forward, looking back. |
| Q39466013 | Beta-adrenergic blockers. |
| Q40093544 | Beta-adrenoceptor blocking drugs and the elderly |
| Q72425575 | Beta-blocking agents |
| Q72429196 | Beta-blocking agents |
| Q69894212 | Beta-blocking effect and pharmacokinetics of pindolol in young and elderly hypertensive patients |
| Q40780745 | Calcium antagonists in the elderly |
| Q39659384 | Cardiovascular disease in the elderly. Arrhythmias |
| Q36329274 | Cardiovascular drug therapy in elderly patients: specific age-related pharmacokinetic, pharmacodynamic and therapeutic considerations |
| Q33545454 | Cardiovascular pharmacology of aging |
| Q72570518 | Clinical experiences in arterial hypertension in the elderly |
| Q38730316 | Clinical pharmacokinetic considerations in the elderly. An update |
| Q46867137 | Clinical pharmacology of dilevalol (III). A pharmacokinetic study of dilevalol in elderly subjects with essential hypertension |
| Q37592754 | Clinical use of beta-adrenoceptor blockade in systemic hypertension |
| Q70399253 | Comparative disposition of pethidine and norpethidine in old and young patients |
| Q34447414 | Comparison of pharmacokinetic profiles of single and multiple doses of a slow release Oros oxprenolol delivery system in young normotensive and elderly hypertensive subjects |
| Q36339974 | Complete Heart Block Presenting as Intermittent Delirium: Case Report and Review of the Literature on Cardiac Disease in the Elderly |
| Q39679813 | Controlled-release formulations of propranolol and verapamil |
| Q71082674 | Disposition of Antipyrine and Phenytoin Correlated with Age and Liver Volume in Man |
| Q39842386 | Drug Kinetics and Hepatic Blood Flow |
| Q40834286 | Drug dosage in the elderly. Is it rational? |
| Q39522004 | Drug metabolism in the elderly |
| Q40147811 | Drug metabolism in the elderly: confounding of age, smoking, and ethanol effects |
| Q34110511 | Drug prescribing for the elderly. |
| Q38353242 | Drug safety and tolerability in prophylactic migraine treatment. |
| Q40077731 | Drug therapy in the elderly |
| Q35674998 | Drugs and the liver. Part III: Ageing of the liver and the metabolism of drugs |
| Q43243898 | Effect of age on plasma propranolol levels |
| Q44150588 | Effect of aging on the pharmacokinetics of acebutolol enantiomers. |
| Q34768828 | Free drug metabolic clearance in elderly people. |
| Q37972280 | Geriatric pharmacokinetics and the kidney |
| Q35802166 | Gut wall metabolism of verapamil in older people: effects of rifampicin-mediated enzyme induction |
| Q70670184 | Health care in the elderly: report of the Technical Group on Use of Medicaments by the Elderly. World Health Organization |
| Q34357692 | Hepatic drug clearance: the effect of age using indocyanine green as a model compound |
| Q38018026 | Hepatic drug metabolism and aging |
| Q83358999 | Hypertension in the elderly |
| Q40287706 | Influence of age and smoking on drug kinetics in man: studies using model compounds |
| Q71352663 | Influence of age on serum protein binding of propranolol |
| Q37832148 | Issues in geriatric drug therapy. |
| Q85177931 | Lack of Grafted Liver Rejuvenation in Adult-to-Pediatric Liver Transplantation |
| Q42084371 | Lack of effect of ageing on the stereochemical disposition of propranolol |
| Q40200138 | Metabolism and excretion of antiarrhythmic drugs |
| Q71650927 | Moricizine Concentration to Guide Arrhythmia Treatment: With Attention to Elderly Patients |
| Q36803114 | Non-small cell lung cancer therapy: safety and efficacy in the elderly |
| Q36834442 | Optimal treatment of angina in older patients |
| Q48187909 | Pharmacodynamics and pharmacokinetics of ethanol, diazepam and pentobarbital in young and aged rats |
| Q41126467 | Pharmacokinetic Parameters and Over-Responsiveness of Iranian Population to Propranolol |
| Q74798758 | Pharmacokinetic and pharmacodynamic changes in the elderly. Clinical implications |
| Q34513277 | Pharmacokinetic and pharmacodynamic characteristics of trazodone in the elderly |
| Q40089241 | Pharmacokinetic aspects of some β-adrenoceptor blocking drugs |
| Q36572624 | Pharmacokinetic dosage guidelines for elderly subjects |
| Q40662274 | Pharmacokinetic studies in elderly people. Are they necessary? |
| Q92136687 | Pharmacokinetic variability of beta-adrenergic blocking agents used in cardiology |
| Q71853080 | Pharmacokinetics and pharmacodynamics of propranolol stereoisomers in hyperthyroid patients |
| Q44127568 | Pharmacokinetics of acebutolol and its main metabolite, diacetolol after oral administration of acebutolol in rabbits with carbon tetrachloride-induced hepatic failure |
| Q51877410 | Pharmacokinetics of lignocaine in the elderly [proceedings] |
| Q71705871 | Pharmacokinetics of metoprolol and its metabolite alpha-OH-metoprolol in healthy, non-smoking, elderly individuals |
| Q70672025 | Pharmacokinetics of metoprolol in healthy, elderly, non-smoking individuals after a single dose and two weeks of treatment |
| Q44802686 | Pharmacokinetics of molsidomine and of its active metabolite, SIN-1 (or linsidomine), in the elderly |
| Q38608296 | Pharmacokinetics of non-prescription sympathomimetic agents |
| Q70672040 | Pharmacokinetics of oral indoramin in elderly and middle-aged female volunteers |
| Q40326082 | Pharmacology and aging |
| Q36972965 | Physiological changes due to age. Implications for cardiovascular drug therapy |
| Q90473694 | Physiologically Based Pharmacokinetic Modelling to Identify Pharmacokinetic Parameters Driving Drug Exposure Changes in the Elderly |
| Q70792979 | Plasma propranolol steady state concentrations in thyroid disorders |
| Q41992666 | Prazosin disposition in young and elderly subjects |
| Q68796563 | Prescription monitoring of drug dosages in the county of Jämtland and Sweden as a whole in 1976, 1982 and 1985 |
| Q51832037 | Protein binding and disposition of lignocaine in the elderly. |
| Q73301280 | Recent advances in pharmacokinetics in elderly |
| Q47232203 | Risk factors contributing to a low darunavir plasma concentration. |
| Q36307244 | The Brain and Propranolol Pharmacokinetics in the Elderly |
| Q36660303 | The Management of Diabetes Mellitus in Older Individuals |
| Q39689342 | The disposition of cytotoxic drugs in the elderly |
| Q72897756 | The effect of age on diurnal variation in the pharmacokinetics of propranolol in hypertensive subjects |
| Q34448597 | The effect of age on the pharmacokinetics of metoprolol and its metabolites |
| Q53846028 | The effect of age upon liver volume and apparent liver blood flow in healthy man. |
| Q60703775 | The effect of ageing on the pharmacokinetics of dihydrocodeine |
| Q34359068 | The effects of age on the pharmacokinetics, antihypertensive efficacy and general tolerability of dilevalol |
| Q68345842 | The efficacy and tolerance to three doses of diltiazem in elderly patients with stable angina |
| Q34448943 | The influence of age, smoking and hyperthyroidism on plasma propranolol steady state concentration |
| Q39761044 | The pharmacokinetics of non-steroidal anti-inflammatory drugs in the elderly |
| Q36706849 | The treatment of hypertension in the elderly |
| Q70450537 | The use of long-acting propranolol ('Inderal' LA) in the management of elderly hypertensive patients |
| Q48535187 | Towards rational drug therapy in old age. The F.E. Williams Lecture 1985. |
| Q72939033 | Toxicity Testing in Relation to Aging |
| Q37764939 | Tuberculosis at extremes of age. |
| Q36077245 | Use of antiarrhythmic drugs in elderly patients |
| Q37079088 | Use of beta-adrenoceptor antagonists in older patients with chronic obstructive pulmonary disease and cardiovascular co-morbidity: safety issues |
| Q34809362 | Use of cardiovascular medications in the elderly |
Search more.